Nogo epitopic fragments for modulating immune response

Details Nogo epitopic fragments for modulating immune response Nogo epitopic fragments for modulating immune response

2011-01-11

2011-01-11

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S326000

Reexamination Certificate

active

07867976

ABSTRACT:
Epitopic fragments of Nogo, including Nogo 45-66, elicit a specific and strong T cell response, and a B cell response. T cells reactive to Nogo antigens are capable of ameliorating ongoing disease, which may be induced with other antigens. The present invention provides compositions and methods for the identification and use of Nogo epitopic fragments in the treatment of immune related disease.

REFERENCES:
patent: 7119165 (2006-10-01), Strittmatter
patent: 7560102 (2009-07-01), Eisenbach-Schwartz et al.
Fontoura, Paulo, et al., “Immunity to the Extracellular Domain of Nogo-A Modulates Experimental Autoimmune Encephalomyelitis”,The Journal of Immunology, Dec. 2004, vol. 173, No. 11, pp. 6981-6992.
Hauben, Ehud, et al., “Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: Comparison with other myelin antigens”, Proc. Natl. Acad. Sci. USA. vol. 98, No. 26, pp. 15173-15178, Dec. 2001.

Affiliated with

Also associated with

Rating

Nogo epitopic fragments for modulating immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nogo epitopic fragments for modulating immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nogo epitopic fragments for modulating immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2668504